4BB — 4Basebio Income Statement
0.000.00%
Last trade - 00:00- £174.33m
- £187.11m
- £0.51m
Annual income statement for 4Basebio, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.202 | 0.462 | 0.338 | 0.268 | 0.506 |
| Cost of Revenue | |||||
| Gross Profit | -0.028 | 0.274 | 0.269 | 0.239 | 0.34 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.622 | 1.08 | 3.87 | 6.11 | 8.56 |
| Operating Profit | -0.42 | -0.622 | -3.53 | -5.84 | -8.05 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.529 | -0.716 | -3.64 | -5.93 | -8.35 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.423 | -0.719 | -3.23 | -5.15 | -7.67 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.423 | -0.719 | -3.23 | -5.15 | -7.67 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.423 | -0.719 | -3.23 | -5.15 | -7.67 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.034 | -0.058 | -0.263 | -0.418 | -0.622 |
| Dividends per Share |